ARS Pharmaceuticals (SPRY) Insider Pratik Shah Buys 30,000 Shares

Pratik Shah Joins Group of Insider Buyers

Pratik Shah acquired 30,000 shares of ARS Pharmaceuticals, Inc. (SPRY) on June 24, 2026. This purchase was part of a coordinated day of activity at the San Diego-based biotechnology company. The acquisition added significantly to Shah's holdings at a time when the company is focusing on the commercialization of its needle-free allergy treatments. The transaction was filed with the Securities and Exchange Commission to disclose the change in ownership.

Broad Leadership Support for ARS Pharmaceuticals

Shah was not the only person at the company adding to their position on June 24, 2026. A group of six other insiders each acquired exactly 30,000 shares on the same day. This group included Phillip Schneider, Saqib Islam, Brent Saunders, Laura Shawver, and Peter Thompson. Additionally, L.P. Ra Capital Management also added 30,000 shares to its holdings. This collective buying activity shows a unified front from the board and major stakeholders as they look toward the company's future development phases.

ARS Pharmaceuticals Stock Performance

On this Saturday, the stock is priced at $8.54 on the Nasdaq. This current price puts the company's market value at roughly $432.6 million. The stock has experienced some volatility over the last year, moving between a low of $4.07 and a high of $13.15. At its current level, the stock is trading right around its 200-day moving average of $8.38, suggesting it is holding onto its long-term trend line despite recent market shifts.

Recent Earnings and Revenue Growth

In its most recent financial updates, ARS Pharmaceuticals reported revenue of $116.93 million. While the company is still in a growth phase and not yet profitable, it has shown substantial revenue expansion. The company reported a net margin of -1.84% and a loss per share of $2.18. Investors are currently looking toward the next scheduled earnings update, which is expected on November 10, 2026.

Analysts Set New Price Targets

Financial firms have remained attentive to the company's progress. On August 13, 2026, Leerink Partners maintained an Outperform rating on the stock, though they adjusted their price target to $18.00 from a previous $24.00. This followed an earlier note on June 25, 2026, where the same firm reiterated its Outperform rating with a $24.00 target. Across four analyst opinions, the stock carries a strong buy consensus with an average price target of $22.50, implying significant potential upside from its current trading price.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biotech company that creates new ways to deliver emergency medicine. Their primary focus is neffy, an intranasal spray designed to deliver epinephrine without a needle. This is intended for people suffering from severe Type I allergic reactions, such as anaphylaxis, providing a more portable and less intimidating alternative to traditional injections. The company's work is critical for patients who need fast-acting treatment during life-threatening allergic emergencies.

What's Ahead for ARS Pharmaceuticals, Inc.

The heavy insider buying from Pratik Shah and his colleagues provides a glimpse into how those running the company view its valuation. While these transactions occurred in June, they remain a point of interest for investors tracking internal confidence. The market's attention will now shift to the November 10 earnings report to see if the company's financial results match the optimism shown by its leadership team.